VivoSeq
Cardiovascular

Ocular Hypertension

119

Pipeline Programs↗

10

Active Trials↗

40

Companies Involved↗

Ocular Hypertension is a highly competitive landscape with 119 programs across 40 companies. The most active players are Roche, EyeD Pharma, Sanofi. 26 therapies are approved with 37 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

19/100

Mech. Concentration

30/100

Completion Rate

96/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1E

EyeD Pharma

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1M

Mati Therapeutics Inc.

3 programs

Phase 2E

Envisia Therapeutics

3 programs

Phase 2O

Ono Pharma USA Inc

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Brimonidine Tartrate

AbbVie

Any Fixed Combination Therapy

AbbVie

Xalacom

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ganforti

AbbVie

Tafluprost

Meitheal

Phase 17

RO5093151

Roche

VISION5 Product

ForSight Vision5, Inc.

Latanoprost Eluting Contact Lens

Massachusetts Eye and Ear Infirmary

RKI983

Novartis

OTX-TIC

Ocular Therapeutix, Inc.

Phase 244

BAY 2701439

Bayer

AMA0076

Amakem, NV

ENV515-3 Travoprost XR

Envisia Therapeutics

ENV515-1 Travoprost XR

Envisia Therapeutics

ENV515-3-2 Travoprost XR

Envisia Therapeutics

Phase 337

Brimonidine

Novartis

Timolol

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Anecortave Acetate

Alcon Research

Phxa41

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Alcon Investigational Agent

Alcon Research

Approved26

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Artificial Tears

University Hospital of Patras

Latanoprost

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Bimatoprost

AbbVie

Pilocarpine

Advanz Pharma

Analysis

Trial Status

276

clinical trials

Completed248 · 90%
Recruiting10 · 4%
Unknown status7 · 3%
Terminated6 · 2%
Withdrawn4 · 1%
Suspended1 · 0%

Clinical Trials

Trial Activity

276 trials

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Recruiting·HHuons Co., Ltd.·Phase 3·NCT07335211·206 enrolled
Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery
Recruiting·EEyeD Pharma·Phase 1·NCT07036510·18 enrolled
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Recruiting·AAmneal Pharmaceuticals, LLC·Phase 1·NCT06267274·240 enrolled
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Recruiting·EEast Coast Institute for Research·Phase 4·NCT06865144·70 enrolled
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Recruiting·BBausch & Lomb Incorporated·Phase 2·NCT07168902·228 enrolled
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Recruiting·MMayo Clinic·Phase 4·NCT07325240·30 enrolled
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
Recruiting·SSanten Pharmaceutical Co., Ltd.·Phase 3·NCT06666855·338 enrolled
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Recruiting·AAmneal Pharmaceuticals, LLC·Phase 3·NCT05401357·168 enrolled
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
Recruiting·AbbVie logoAbbVie·Phase 1/2·NCT04499248·96 enrolled
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo
Recruiting·UUniversity of Maryland, Baltimore·Approved·NCT04401982·50 enrolled
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
Completed·PPolyActiva Pty Ltd·Phase 1·NCT05333419·1 enrolled
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Completed·AbbVie logoAbbVie·Phase 3·NCT01177098·561 enrolled
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
Completed·FForSight Vision5, Inc.·Phase 2·NCT01915940·169 enrolled
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Completed·AbbVie logoAbbVie·Phase 4·NCT02003534·376 enrolled
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Completed·Roche logoRoche·Phase 1·NCT02622334·45 enrolled
Page 1 of 19

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)